GW Pharmaceuticals PLC- (NASDAQ:GWPH) Given Consensus Rating of “Buy” by Brokerages

GW Pharmaceuticals PLC- (NASDAQ:GWPH) has been assigned an average rating of “Buy” from the fifteen ratings firms that are covering the stock, MarketBeat reports. Three research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $204.36.

A number of equities analysts have weighed in on the stock. JPMorgan Chase & Co. assumed coverage on shares of GW Pharmaceuticals PLC- in a research report on Thursday, January 2nd. They issued an “overweight” rating and a $134.00 price target for the company. Zacks Investment Research lowered shares of GW Pharmaceuticals PLC- from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Evercore ISI assumed coverage on shares of GW Pharmaceuticals PLC- in a research report on Friday, February 7th. They issued a “buy” rating and a $260.00 price target for the company. HC Wainwright reiterated a “buy” rating and issued a $170.00 price target on shares of GW Pharmaceuticals PLC- in a research report on Wednesday, December 18th. Finally, Needham & Company LLC assumed coverage on shares of GW Pharmaceuticals PLC- in a research report on Monday, October 21st. They issued a “buy” rating and a $200.00 price target for the company.

Shares of GWPH traded up $0.46 during mid-day trading on Friday, reaching $126.60. The stock had a trading volume of 155,720 shares, compared to its average volume of 582,269. The firm has a market cap of $4.00 billion, a price-to-earnings ratio of -64.26 and a beta of 2.19. GW Pharmaceuticals PLC- has a 12 month low of $95.71 and a 12 month high of $196.00. The business has a fifty day moving average of $113.35 and a 200 day moving average of $123.42. The company has a debt-to-equity ratio of 0.03, a quick ratio of 6.60 and a current ratio of 7.33.

In related news, CEO Justin D. Gover sold 5,340 shares of the company’s stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $9.17, for a total transaction of $48,967.80. Following the sale, the chief executive officer now owns 568,865 shares of the company’s stock, valued at $5,216,492.05. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Chairman Geoffrey W. Dr Guy sold 900,000 shares of the stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $9.44, for a total transaction of $8,496,000.00. Following the completion of the sale, the chairman now directly owns 7,421,521 shares in the company, valued at approximately $70,059,158.24. The disclosure for this sale can be found here. Insiders sold 908,916 shares of company stock worth $8,575,650 in the last three months. Insiders own 3.60% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the company. Signaturefd LLC raised its stake in shares of GW Pharmaceuticals PLC- by 192.5% in the third quarter. Signaturefd LLC now owns 234 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 154 shares during the period. Valeo Financial Advisors LLC raised its position in shares of GW Pharmaceuticals PLC- by 322.6% in the 3rd quarter. Valeo Financial Advisors LLC now owns 262 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 200 shares during the last quarter. Trustcore Financial Services LLC raised its position in shares of GW Pharmaceuticals PLC- by 54.6% in the 4th quarter. Trustcore Financial Services LLC now owns 283 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 100 shares during the last quarter. Squar Milner Financial Services LLC raised its position in shares of GW Pharmaceuticals PLC- by 300.0% in the 3rd quarter. Squar Milner Financial Services LLC now owns 300 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 225 shares during the last quarter. Finally, PSI Advisors LLC purchased a new position in shares of GW Pharmaceuticals PLC- in the 4th quarter valued at approximately $41,000. 84.10% of the stock is currently owned by institutional investors and hedge funds.

GW Pharmaceuticals PLC- Company Profile

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.

Featured Article: Depreciation

Analyst Recommendations for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.